**Proteins** 

# **Screening Libraries**

## **Product** Data Sheet

# L-Leucine-<sup>13</sup>C<sub>6</sub>, <sup>15</sup>N

Cat. No.: HY-N0486S8 CAS No.: 202406-52-8  $^{13}C_6H_{13}^{15}NO_2$ Molecular Formula:

Molecular Weight: 138.12

Target: mTOR; Endogenous Metabolite

In solvent

Pathway: PI3K/Akt/mTOR; Metabolic Enzyme/Protease

Storage: Powder -20°C

> 4°C 2 years -80°C 6 months

3 years

-20°C 1 month

### **SOLVENT & SOLUBILITY**

H<sub>2</sub>O: 6.25 mg/mL (45.25 mM; Need ultrasonic) In Vitro

PBS (pH 7.2) : ≥ 1 mg/mL (7.24 mM)

\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	7.2401 mL	36.2004 mL	72.4008 mL
	5 mM	1.4480 mL	7.2401 mL	14.4802 mL
	10 mM	0.7240 mL	3.6200 mL	7.2401 mL

Please refer to the solubility information to select the appropriate solvent.

### **BIOLOGICAL ACTIVITY**

L-Leucine. 13C<sub>6</sub>, 15N is the 13C- and 15N-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which Description activates the mTOR signaling pathway[1].

In Vitro Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### **REFERENCES**

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com